Kornimate/medical-research-clean huggingface dataset:
nasal irrigation in infants with bronchiolitis.

Conditions: Bronchiolitis

Summary: bronchiolitis is a leading cause of acute illness and hospitalization in the first year of life. most children with bronchiolitis have mild disease and are managed at home with support from primary care providers, while children with more severe symptoms require supportive therapy with oxygen and fluid administration. neonates may be obligate nasal breathers until they are at least 2 months old and nasal obstruction may play a relevant role in respiratory resistances throughout the first months of life, whereas nasal passages may exhibit as much as 50% of the total airway resistance. some guidelines recommend to clear the nostrils of secretions to improve airway patency but no controlled trial on the efficacy of nasal irrigation in infants with bronchiolitis was carried out. the aim of this randomized controlled trial is to compare normal saline and hypertonic solution for nasal irrigation versus simple supportive care in infants admitted to emergency department with bronchiolitis and mild desaturation.


Eligibility criteria:
inclusion criteria: * infants \<1 year * diagnosis of bronchiolitis with respiratory distress, rhinitis, cough * oxygen saturation between 88 and 94% exclusion criteria: * previous treatments (nasal irrigation or suctioning, oxygen, nebulized drugs, nebulized hypertonic solution, antipyretics up to 6 hours before the study entry, oral steroids at any time before study entry) * chronic illness

Keywords: bronchiolitis normal saline solution hypertonic solution nasal irrigation
a comparison of the first attempt success rate of cannulation between the accuvein apparatus and standard technique

Conditions: Procedural Complication

Summary: background: the accuvein av300 device helps in venepuncture and intravenous (iv) cannulation. it uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface. objectives: to assess the effectiveness of the av300 device over the standard technique in increasing the ﬁrst-time success rate (sr) for pediatric patients who needed iv cannulation. methods: this was a prospective cross study of patients aged 0-18 years scheduled for surgery or examination under anesthesia but without having an existing iv access and after providing consent form. patients were randomized into two groups; cannulation with av300 or standard insertion performed by experienced pediatric anesthesiologists and residents under training.

patients who fulfilled the inclusion criteria and provided informed consent were assigned to one of two groups using a randomization program that assigned research participants into group a (accuvein av300 assisted intravenous catheter insertion) or group b (standard technique of insertion of the intravenous cannula). after pre-anesthetic evaluation, the research participant was brought to the operating room and standard monitoring were applied (ekg, spo2, bp) if tolerated. anesthesia was induced via face mask with sevoflurane in 100% o2. the anesthesiologist and resident decided on a site believed to be the best for cannulation and on the size of the venous cannula as 22g or 24g. when the supervising anesthesiologist deemed it appropriate, the venous cannulation was attempted, according to the randomization groups, either with the accuvein device (group a) or blindly (group b). a rating of the vein attempted as either difficult or easy was established by the attending anesthesiologist.

Eligibility criteria:
inclusion criteria: * patients less than 18 years of age, american society of anesthesiologist physical status (asa) status i, ii or iii, undergoing elective surgery or examination under anesthesia, which did not have existing intravenous access. exclusion criteria: * existing intravenous access, malformations or infections at the potential site of insertion, need for emergency surgery, and inability or unwillingness of parent or legal guardian to give written informed consent.
effect of virtual reality on dental patients

Conditions: Child Behavior Problem; Anxiety, Dental

Summary: clinicians should appreciate the effectiveness of virtual reality (vr) headsets for managing both the anxiety and the behaviour of dental patients. the aim of this study was to assess the effectiveness of using a vr headset as a distraction for managing the anxiety and behaviour of patients during their dental treatment related to underlying psychological factors.


Eligibility criteria:
inclusion criteria: * healthy volunteers with dental needs. * children with parental consent exclusion criteria: * patients with cognitive impairments

Keywords: virtual reality dental anxiety behaviour psychological factors
the impact of mtm model on the efficacy and safety of anticoagulant therapy in postoperative colorectal cancer patients

Conditions: Thrombosis, Venous

Summary: anticoagulants are classified as high-risk medications, with their main adverse drug events (ades) being recurrent venous thromboembolism (vte) and bleeding events.postoperative colorectal cancer (crc) patients exhibit a high probability of recurrent vte and bleeding during anticoagulation therapy.the medication therapy management (mtm) model will contribute to reducing ades associated with anticoagulants in crc patients.

anticoagulants are classified as high-risk medications, with their main adverse drug events (ades) being recurrent venous thromboembolism (vte) and bleeding events.postoperative colorectal cancer (crc) patients exhibit a high probability of recurrent vte and bleeding during anticoagulation therapy. in clinical practice, a considerable proportion of patients have experienced inappropriate prescribing of anticoagulants. following a bleeding event, the decision on whether and when to initiate anticoagulation therapy requires individualized assessment by physicians and pharmacists based on each patient's specific condition. moreover, over a quarter of patients prematurely discontinue anticoagulation therapy, which substantially increases their risk of vte recurrence.effective management of the use of anticoagulants holds significant importance. pharmacist-led anticoagulation management can significantly improve the appropriateness of anticoagulant therapy and reduce total bleeding risk. however, the efficacy of various intervention approaches, such as medication reconciliation and medication monitoring, as well as the timing of intervention, has not been conclusively established. this study integrates multifaceted pharmacist interventions within the medication therapy management (mtm) model, intervening at patient admission, during hospitalization, and post-discharge, to evaluate the impact of the mtm model on the efficacy and safety of anticoagulation therapy.

Eligibility criteria:
inclusion criteria: 1. patients with histologically confirmed crc and symptomatic or incidental vte who received anticoagulant treatment. 2. crc patients with vte treated with an anticoagulant for at least 3 moths. exclusion criteria: 1.participation in this study required active anticoagulant treatment. apart from this, there were no specific exclusion criteria.
role of computed tomography in evaluation of different causes of intestinal obstruction correlated with operative findings

Conditions: Intestinal Obstruction

Summary: intestinal obstruction is a common clinical problem that occurs secondary to mechanical or functional obstruction of the intestine, preventing normal transit of its contents. it is a frequent cause of hospitalization and represents 15-20% of surgical admissions for acute abdominal pain . the underlying aetiology of large bowel obstructions (lbos) is age dependent, but in adulthood, the most common cause is colonic cancer (50-60%), typically in the sigmoid. the second most common cause in adults is acute diverticulitis (involving the sigmoid colon). together, obstructing tumors and acute diverticulitis account for 90% of all causes of lbo. adhesions are the most common cause of small bowel obstruction (sbo) , for practical purposes, they do not tend to cause lbo.other causes which cause symptoms that are mimic intestinal obstruction as in bowel ischemia that mainly caused by mesenteric vessels occlusion (adynamic obstruction). computed tomography (ct) has become a mainstay in diagnosing bowel obstruction. this is because the management of obstruction has dramatically changed with a decrease in the proportion of patients who need surgery multi detector computed tomography scanners provide a huge gain in performance that can be used to reduce the scan time, reduce section collimation, or to increase scan length surgery. diagnosis of intestinal obstruction is established by patient history and clinical findings include abdominal distension, acute abdominal pain, vomiting and inability to pass stools or flatus . the role of ct in diagnosing intestinal obstruction has been expanding by determining presence, degree, level and cause (extrinsic lesions, intrinsic lesions, intussusception, intraluminal lesions) of obstruction and in identifying any associated strangulation, and also it has an important role in diagnosing the mesenteric vessels obstruction by thrombi by injection of iv contrast media which causes adynamic bowel obstruction .


Eligibility criteria:
inclusion criteria: * any age group and gender presented by manifestations of acute intestinal obstruction. exclusion criteria: * pregnant women.
wellness engagement project, petersburg

Conditions: Obesity

Summary: this study tests the feasibility of a health and wellness trial designed with community input. this 12-week program will be tested over a 24-week period using a delayed treatment control group.

this 12-week program was designed based on input from petersburg, va community residents, collected through various methods over a two-year period. the 12 week program is designed to impact three levels: individual, family and community. at the individual level, participants receive print material lessons related to healthy eating and increasing physical activity, as well as videos that model these lessons; participants will also have access to a peer support coach who will contact them on a biweekly basis and are trained to help them identify and reach their own personal health goals. at the family level, participants are encouraged to share all of the information they receive as a part of this program with the rest of their family, and are asked to begin walking regularly and to attend fitness and nutrition classes held within their neighborhood (by the we program) with family members. on a community level, local church groups and neighborhood organizations will receive assistance in launching walking clubs, and all community residents are invited to attend the physical activity and nutrition classes that the we project hosts within the community.

Eligibility criteria:
inclusion criteria: * age between 18-65 years. * must have a school going child between 12-17 living in the home. * bmi between 25 and 50 kg/m2. exclusion criteria: * report not being able to walk 2 blocks (1/4 mile) without stopping * currently participating in another weight loss program * taking a weight loss medication * have a history of bariatric surgery * pregnant or plan to become pregnant during the intervention timeframe * report an unsupervised heart condition, chest pain during periods of rest or activity, or loss of consciousness on the physical activity readiness questionnaire * report a medical condition that would jeopardize their safety if involved in a weight management program with diet and exercise guidelines (e.g., uncontrolled heart problem) * fail medical screening by study medical staff) * report conditions that, in the judgment of the pi, would render the participant unlikely to follow the study protocol (e.g., planned move from the area, dementia, substance abuse).
bioequivalence study of cefprozil tablets, usp 500 mg undef fed conditions

Conditions: Healthy

Summary: the objective of this study is to assess the single - dose relative bioavailability of ranbaxy and bristol-myers squibb company (cefzil ®) 500 mg cefprozil tablets, under fed conditions.

a single dose, randomized, two-period, two-treatment, two-sequence crossover study design was used to evaluate the relative bioavailability of the cefprozil tablet products when dosed (1 x 500 mg) under fed conditions. the washout period will be at least 14 days between doses. twenty four plus two alternate (24 + 2) subjects were enrolled in this study and all volunteers were healthy adults. twenty six (24 + 2) subjects began the study, and twenty-five (23 + 2) subjects completed the clinical portion of the study in its entirety.

Eligibility criteria:
inclusion criteria: * subject candidates must fulfill all of the following inclusion criteria t be eligible for participation in the study, unless otherwise specified: 1. healthy adult male or female volunteers, 18 to 55 years of age 2. weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (table of 'desirable weights of adults', metropolitan life insurance company, 1983) 3. medically healthy subjects with clinically normal laboratory profiles and ecgs 4. females of child bearing potential should either be sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or be using one of the following acceptable birth control methods: * surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum * iud in place for at least 3 months * barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose and throughout the study * surgical sterilization of the partner (vasectomy for 6 months minimum) * hormonal contraceptives for at least 3 months prior to the first dose of the study * other birth control methods may be deemed acceptable e) post menopausal women with amenorrhea for at least 2 years will be eligible f) voluntarily consent to participate in the study exclusion criteria: * subject candidates must not be enrolled in the study if they meet any of the following criteria: 1. history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease 2. in addition, history or presence of: * alcohol or drug abuse within the past year * hypersensitivity or idiosyncratic reaction to cefprozil, other cephalosporin antibiotics, or penicillin c) female subjects who are pregnant or lactating d) subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study e) subjects who through completion of the study, would have donated in excess of: * 500 ml of blood in 14 days * 1500 ml of blood in 180 days * 2500 ml of blood in 1 year f) subjects who have participated in another clinical trial within 28 days prior to the first dose.

Keywords: bioequivalence cefprozil 500mg tablets fed conditions
adoptive treatment of advanced hepatocellular carcinoma with allogeneic γδ-t cells

Conditions: Advanced Hepatocellular Carcinoma

Summary: brief summary: in this study, effects of γδ t cells on advanced hepatocyte carcinoma the goal of this clinical trial is to learn about effects of allogeneic γδ t therapy in advanced hepatocyte carcinoma patients. the main question it aims to answer is:will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ t therapy? participants will received gdkm-100injection (allo-γδ t cells) infusion every two weeks.


Eligibility criteria:
inclusion criteria 1. age is 18-75 years old, and gender is unlimited; 2. hcc was confirmed by pathological or clinical examination; 3. patients with stage cnlciii, iv primary hcc who are receiving second-line treatment / unable to receive existing treatments, or cnlci and ii of primary hcc patients who are unable to receive existing treatments; 4. male subjects with partner women of childbearing age must have reliable, effective methods of contraception starting from the signing of the informed consent form until 120 days after the last dose of the study drug. male subjects with a pregnant spouse must use condoms without other contraceptive methods; 5. participants volunteered to join the study, signed an informed consent, had good compliance, and cooperated with the follow-up. exclusion criteria 1. gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome; 2. accept other cellular or immune clinical experiments within 8 weeks before enrollment; 3. immunological deficiency, a known immunosuppressive disease or hiv; 4. active infection, unexplained fever; 5. serious or unstable heart, lung, kidney and hematopoietic system diseases; 6. autoimmune diseases, such as rheumatoid arthritis; 7. neurological diseases, diffuse leptomeningeal diseases; combined with neurodegenerative diseases; 8. hormone use during cell therapy: dexamethasone dose exceeds 2mg / day during immunotherapy; 9. pregnant or lactating women; 10. the subject had a known history of psychotropic substance abuse or drug use; he had stopped drinking patients can be enrolled; 11 in the judgment of the investigator, the subject has other factors that may cause the forced termination of the study, such as other serious diseases or serious abnormal laboratory examination or other family or social factors that will affect the subject's safety of the subject, or the collection of trial data and samples.

Keywords: hepatocellular carcinoma gamma delta t cell allogeneic adoptive treatment
clinical study to evaluate mavacamten (myk-461) in adults with symptomatic obstructive hypertrophic cardiomyopathy

Conditions: Obstructive Hypertrophic Cardiomyopathy

Summary: this is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive hcm (ohcm). approximately 220 participants will be randomized to receive placebo or mavacamten.


Eligibility criteria:
key inclusion criteria: * age 18 and greater, body weight ≥ 45kg * has adequate acoustic windows to enable accurate transthoracic echocardiograms (ttes) * diagnosed with ohcm consistent with current american college of cardiology foundation/american heart association and european society of cardiology guidelines and satisfy both criteria: * has documented left ventricular ejection fraction (lvef) ≥55% * nyha class ii or iii * has documented oxygen saturation at rest ≥90% at screening * is able to perform an upright cpet and has a respiratory exchange ratio (rer) ≥1.0 at screening per central reading key exclusion criteria: * known infiltrative or storage disorder causing cardiac hypertrophy that mimics ohcm, such as fabry disease, amyloidosis, or noonan syndrome with lv hypertrophy * history of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening * history of resuscitated sudden cardiac arrest (at any time) or known history of appropriate implantable cardioverter defibrillator (icd) discharge for life-threatening ventricular arrhythmia within 6 months prior to screening * paroxysmal, intermittent atrial fibrillation with atrial fibrillation present at screening * persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to screening and/or not adequately rate controlled within 6 months prior to screening * treatment (within 14 days prior to screening) or planned treatment during the study with disopyramide or ranolazine * treatment (within 14 days prior to screening) or planned treatment during the study with a combination of β-blockers and calcium channel blockers * lvot gradient with valsalva maneuver \<30 mmhg at screening * has been successfully treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[asa\]) within 6 months prior to screening or plans to have either of these treatments during the study * icd placement within 2 months prior to screening or planned icd placement during the study * has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion * prior treatment with cardiotoxic agents such as doxorubicin or similar

Keywords: symptomatic, left ventricular outflow tract gradient
striveweekly: self-guided online intervention for anxiety, depression, and stress in university students

Conditions: Anxiety; Depressive Symptoms; Stress, Psychological

Summary: this study was a randomized controlled trial of an original online mental health promotion program. this study aimed to: 1) establish program effectiveness by examining symptom change between conditions and 2) examine predictors of symptom change. the program was previously tested in open trial feasibility study by the same principal investigator and has since been rebuilt as informed by feasibility findings and participant qualitative feedback. participants were randomly assigned to either a waitlist condition or eight weeks of the intervention condition. baseline, posttest, and follow-up electronic surveys collected self-reported symptoms of stress, anxiety, and depression. motivational variables were also assessed at baseline and then tested as moderators of intervention effects.


Eligibility criteria:
inclusion criteria: * enrolled as a student at ucla (fall 2017 - winter 2018) exclusion criteria: * concurrent enrollment in a similar online anxiety and depression treatment study on campus * invalid data reporting (e.g., straight-lined responses to surveys) -- post hoc exclusion
mobile application for integrative diabetes care

Conditions: Diabetes Mellitus, Type 2; Depression

Summary: the investigators have developed a mobile application named 'dangdang care' (which conveys the meaning of managing diabetes confidently and consistently through psychological care) designed to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms. the application incorporates a behavioral activation program. subsequently, the investigators conducted a 12-week randomized controlled trial, enrolling individuals with type 2 diabetes and mild-to-moderate depression, with the assistance of public health centers. the trial aimed to assess the effectiveness and feasibility of the application in promoting consistent diabetes management through added psychological care.


Eligibility criteria:
inclusion criteria: * adults aged 20 to 80 years with type 2 diabetes * individuals belonging to disadvantaged populations, such as medical aid beneficiaries or those classified as low-income groups * mild-to-moderate depressive symptoms, defined as a patient health questionnaire-9 (phq-9) score between 5 and 19 * capable of reading and understanding korean and using a mobile application * having a clear understanding of the study's purpose and providing written consent exclusion criteria: * type 1 diabetes or gestational diabetes * diabetes complications that hindered diabetes self-management * severe depressive symptoms that made app usage and completion of the self-report questionnaire difficult * serious mental illnesses other than depressive symptoms (e.g., schizophrenia and related disorders, bipolar and related disorders, or neurodegenerative disorders) * serious life-threatening medical conditions * physical conditions that impeded mobility * a history of traumatic brain injury * unwillingness to complete the questionnaire and provide personal information
the safety and efficacy of psilocybin in participants with type 2 bipolar disorder (bp-ii) depression.

Conditions: Treatment Resistant Depression

Summary: the primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with bp-ii, current episode depressed, in improving depressive symptoms.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 bipolar disorder (bp-ii) depression exclusion criteria: * comorbidities